Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Graves’ Orbitopathy: Reevaluating Rundle’s Curve
source: Thyroid
year: 2018
authors: W Pinto, D Villagelin, RB Santos, N Perini, A Fontanesi Oliveira, C Zampieri, H Paranhos Louback, L Santos Caleffi, W Muller Ferreira Tirapani, J Hamilton Romaldini
summary/abstract:Graves’ orbitopathy (GO) is the most common extrathyroidal manifestation of Graves’ disease (GD). According to Rundle’s curve, GO is characterized by an initial phase of increasing activity (inflammatory phase), a severity peak, and a stable plateau phase (fibrotic phase). This overview has an implication in GO therapeutics. Different patterns that are still distinct from Rundle’s curve have not yet been described.
There were 567 patients with GD from a single clinical center, who were analyzed according to the Clinical Activity Score (CAS) for GO activity. GO evolution was evaluated every 6 months using the CAS. The patients were divided into 2 groups according to the GO evolution: Group 1 (G1): patients who follow Rundle curve; Group 2 (G2): patients whose characteristics followed GO improvement and worsening over time. Follow-up in both groups was seen at 60 months.
From 567 initial patients, 204 patients were included. G1 (n = 132), mean (– SD), age at diagnosis was 39 – 11 years, 80% were female, with smoking present in 36% of patients. TSH and free T4 were 0.014 – 0.026 IU/mL and 4.40 – 2.09 ng/dL, respectively. Thyrotropin receptor antibodies (TRAb) were positive in 84% patients. In G2 (n = 72), age at diagnosis was 41 – 11 years, 73% were female, and smoking was present in 51% of patients. TSH and free T4 were 0.017 – 0.031 IU/mL and 3.92 – 1.82 ng/dL, respectively. TRAb were positive in 85% patients. Both groups had similar characteristics except for smoking (p < 0.05).
organization: Universidade Estadual de Campinas, BrazilDOI: 10.1089/thy.2018.29065.abstracts
read more
Related Content
-
Does Treatment of Graves’ Disease Modify The Long-Term Course of Graves’ Orbitopathy?Introduction: Graves’ orbitopathy (GO...
-
Dealing With Thyroid Eye Disease: Patient and Physician PerspectivesJoin us for a webinar hosted by the Grav...
-
“TED Today” Episode 5https://www.facebook.com/ThyroidEyes/vid...
-
Anatomic Considerations in Thyroid Eye DiseasePurpose: To review and summarize the cl...
-
Elizabeth A. Bradley, MDElizabeth A. Bradley is an ophthalmologi...
-
“TED Today” Episode 3https://www.youtube.com/watch?v=NqM9kf1h...
-
Thyroid Eye Disease and the Role of the TED SpecialistNot all people with thyroid disease have...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.